Modafinil is a eugeroic that has been accepted by the FDA in 1998 as a treatment for numerous disorders such as shift work sleep disorders, enhanced daytime sleepiness and shift work sleep disorder (Saletu &Saletu-Zyhlarz, 2013, 231). This drug possesses similar traits to amphetamines and improves the previously mentioned conditions by stimulating neural activity. According to its chemical structure and properties, Modafinil may be classified as a CNS stimulant however; the drug interestingly is not accompanied with side effects that are observed after usage of drugs in the same classification (Saletu &Saletu-Zyhlarz, 2013, 231). Side effects that are common in CNS stimulants but are not observed in Modafinil users include arterial hypertension and tachycardia. The absence of these effects has been widely attributed to the drug’s mechanism of action, though the exact principles of this yet to be established. The paper will focus on the positive effects of the drug and its pharmacokinetics on neural activity.